NYSEAMERICAN:ARMP Armata Pharmaceuticals Q2 2026 Earnings Report $5.06 +0.55 (+12.20%) Closing price 07/20/2026 04:10 PM EasternExtended Trading$4.69 -0.37 (-7.39%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Armata Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.48Beat/MissN/AOne Year Ago EPSN/AArmata Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$0.40 millionBeat/MissN/AYoY Revenue GrowthN/AArmata Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Armata Pharmaceuticals Earnings HeadlinesArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02July 20 at 2:10 PM | finanznachrichten.deArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02July 20 at 7:00 AM | prnewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 21 at 1:00 AM | Altimetry (Ad)Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is EverythingJuly 17, 2026 | seekingalpha.comArmata Pharmaceuticals Stock Short Interest Report | AMEX:ARMP | BenzingaJuly 13, 2026 | benzinga.comArmata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus BacteremiaJuly 13, 2026 | prnewswire.comSee More Armata Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email. Email Address About Armata PharmaceuticalsArmata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings. Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats. Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.View Armata Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
